STAAR Surgical (STAA) Scheduled to Post Quarterly Earnings on Tuesday

STAAR Surgical (NASDAQ:STAA - Get Free Report) will be issuing its quarterly earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of $0.05 per share for the quarter. STAAR Surgical has set its FY24 guidance at $0.70 EPS.Individual interested in registering for the company's earnings conference call can do so using this link.

STAAR Surgical (NASDAQ:STAA - Get Free Report) last posted its quarterly earnings data on Monday, February 26th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). The business had revenue of $76.27 million during the quarter, compared to the consensus estimate of $75.94 million. STAAR Surgical had a net margin of 6.62% and a return on equity of 8.73%. The business's revenue for the quarter was up 19.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.04 EPS. On average, analysts expect STAAR Surgical to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

STAAR Surgical Stock Performance

Shares of STAA stock traded down $1.47 during trading on Tuesday, hitting $45.96. The company had a trading volume of 417,510 shares, compared to its average volume of 738,314. The stock's 50-day moving average price is $40.19 and its 200 day moving average price is $35.69. STAAR Surgical has a one year low of $26.66 and a one year high of $73.13. The firm has a market capitalization of $2.26 billion, a P/E ratio of 106.88 and a beta of 0.85.

Analyst Ratings Changes

STAA has been the subject of a number of recent analyst reports. Mizuho upped their price target on shares of STAAR Surgical from $45.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, April 11th. William Blair upgraded STAAR Surgical from a "market perform" rating to an "outperform" rating in a research note on Thursday, April 4th. Needham & Company LLC reissued a "hold" rating on shares of STAAR Surgical in a report on Thursday, April 4th. Canaccord Genuity Group upped their target price on STAAR Surgical from $32.00 to $46.00 and gave the stock a "hold" rating in a report on Monday, April 8th. Finally, Piper Sandler cut their target price on shares of STAAR Surgical from $40.00 to $33.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 27th. Seven equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $46.38.

Insiders Place Their Bets

In other STAAR Surgical news, Director Aimee S. Weisner acquired 1,750 shares of the company's stock in a transaction that occurred on Thursday, March 14th. The shares were acquired at an average price of $38.11 per share, with a total value of $66,692.50. Following the completion of the purchase, the director now directly owns 10,864 shares of the company's stock, valued at approximately $414,027.04. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.10% of the company's stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.